Literature DB >> 24943134

Unmasked Brugada pattern by ajmaline challenge in patients with myotonic dystrophy type 1.

Thomas Pambrun1, Agustín Bortone, Patrick Bois, Bruno Degand, Sylvie Patri, Aurélie Mercier, Mohamed Chahine, Aurélien Chatelier, Damien Coisne, Alain Amiel.   

Abstract

BACKGROUND: Myotonic dystrophy type 1 (DM1) generates missplicing of the SCN5A gene, encoding the cardiac sodium channel (Nav 1.5). Brugada syndrome, which partly results from Nav 1.5 dysfunction and causes increased VF occurrence, can be unmasked by ajmaline. We aimed to investigate the response to ajmaline challenge in DM1 patients and its potential impact on their sudden cardiac death risk stratification.
METHODS: Among 36 adult DM1 patients referred to our institution, electrophysiological study and ajmaline challenge were performed in 12 patients fulfilling the following criteria: (1) PR interval >200 ms or QRS duration >100 ms; (2) absence of complete left bundle branch block; (3) absence of permanent ventricular pacing; (4) absence of implantable cardioverter-defibrillator (ICD); (5) preserved left-ventricular ejection fraction >50%; and (6) absence of severe muscular impairment. Of note, DM1 patients with ajmaline-induced Brugada pattern (BrP) were screened for SCN5A.
RESULTS: In all the 12 patients studied, the HV interval was <70 ms. A BrP was unmasked in three patients but none carried an SCN5A mutation. Ajmaline-induced sustained ventricular tachycardia occurred in one patient with BrP, who finally received an ICD. The other patients did not present any cardiac event during the entire follow-up (15 ± 4 months).
CONCLUSION: Our study is the first to describe a high prevalence of ajmaline-induced BrP in DM1 patients. The indications, the safety, and the implications of ajmaline challenge in this particular setting need to be determined by larger prospective studies.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Brugada syndrome; ajmaline challenge; cardiac arrhythmia; myotonic dystrophy type 1; sodium channels

Mesh:

Substances:

Year:  2014        PMID: 24943134      PMCID: PMC6931494          DOI: 10.1111/anec.12168

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  23 in total

1.  99th ENMC international workshop: myotonic dystrophy: present management, future therapy. 9-11 November 2001, Naarden, The Netherlands.

Authors:  P S Harper; B G M van Engelen; B Eymard; M Rogers; D Wilcox
Journal:  Neuromuscul Disord       Date:  2002-08       Impact factor: 4.296

2.  Insights into the location of type I ECG in patients with Brugada syndrome: correlation of ECG and cardiovascular magnetic resonance imaging.

Authors:  C Veltmann; T Papavassiliu; T Konrad; C Doesch; J Kuschyk; F Streitner; D Haghi; H J Michaely; S O Schoenberg; M Borggrefe; C Wolpert; R Schimpf
Journal:  Heart Rhythm       Date:  2011-11-23       Impact factor: 6.343

3.  2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).

Authors:  Michele Brignole; Angelo Auricchio; Gonzalo Baron-Esquivias; Pierre Bordachar; Giuseppe Boriani; Ole-A Breithardt; John Cleland; Jean-Claude Deharo; Victoria Delgado; Perry M Elliott; Bulent Gorenek; Carsten W Israel; Christophe Leclercq; Cecilia Linde; Lluís Mont; Luigi Padeletti; Richard Sutton; Panos E Vardas
Journal:  Europace       Date:  2013-06-24       Impact factor: 5.214

4.  Arrhythmia exacerbation after sodium channel blockade in myotonic dystrophy type 1.

Authors:  Richard F Otten; John A Scherschel; John C Lopshire; Deepak Bhakta; Robert M Pascuzzi; William J Groh
Journal:  Muscle Nerve       Date:  2009-11       Impact factor: 3.217

Review 5.  Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association.

Authors:  Charles Antzelevitch; Pedro Brugada; Martin Borggrefe; Josep Brugada; Ramon Brugada; Domenico Corrado; Ihor Gussak; Herve LeMarec; Koonlawee Nademanee; Andres Ricardo Perez Riera; Wataru Shimizu; Eric Schulze-Bahr; Hanno Tan; Arthur Wilde
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

6.  Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium.

Authors:  Koonlawee Nademanee; Gumpanart Veerakul; Pakorn Chandanamattha; Lertlak Chaothawee; Aekarach Ariyachaipanich; Kriengkrai Jirasirirojanakorn; Khanchit Likittanasombat; Kiertijai Bhuripanyo; Tachapong Ngarmukos
Journal:  Circulation       Date:  2011-03-14       Impact factor: 29.690

7.  Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.

Authors:  J Mathieu; H Boivin; D Meunier; M Gaudreault; P Bégin
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

8.  A muscleblind knockout model for myotonic dystrophy.

Authors:  Rahul N Kanadia; Karen A Johnstone; Ami Mankodi; Codrin Lungu; Charles A Thornton; Douglas Esson; Adrian M Timmers; William W Hauswirth; Maurice S Swanson
Journal:  Science       Date:  2003-12-12       Impact factor: 47.728

9.  Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1.

Authors:  Karim Wahbi; Vincent Algalarrondo; Henri Marc Bécane; Véronique Fressart; Chérif Beldjord; Kamel Azibi; Arnaud Lazarus; Nawal Berber; Hélène Radvanyi-Hoffman; Tanya Stojkovic; Anthony Béhin; Pascal Laforêt; Bruno Eymard; Stéphane Hatem; Denis Duboc
Journal:  Arch Cardiovasc Dis       Date:  2013-10-17       Impact factor: 2.340

10.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

View more
  5 in total

1.  SCN4A variants and Brugada syndrome: phenotypic and genotypic overlap between cardiac and skeletal muscle sodium channelopathies.

Authors:  Véronique Bissay; Sophie C H Van Malderen; Kathelijn Keymolen; Willy Lissens; Uschi Peeters; Dorien Daneels; Anna C Jansen; Gudrun Pappaert; Pedro Brugada; Jacques De Keyser; Sonia Van Dooren
Journal:  Eur J Hum Genet       Date:  2015-06-03       Impact factor: 4.246

Review 2.  Heart Disease in Disorders of Muscle, Neuromuscular Transmission, and the Nerves.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

Review 3.  Brugada syndrome in children - Stepping into unchartered territory.

Authors:  Shashank P Behere; Steven N Weindling
Journal:  Ann Pediatr Cardiol       Date:  2017 Sep-Dec

4.  Brugada syndrome in a young patient with type 1 myotonic dystrophy requiring an implantable cardioverter defibrillator for primary prevention: a case report.

Authors:  Panagiotis Korantzopoulos; Aris Bechlioulis; Lampros Lakkas; Katerina K Naka
Journal:  Eur Heart J Case Rep       Date:  2019-06-01

5.  Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy.

Authors:  Fernande Freyermuth; Frédérique Rau; Yosuke Kokunai; Thomas Linke; Chantal Sellier; Masayuki Nakamori; Yoshihiro Kino; Ludovic Arandel; Arnaud Jollet; Christelle Thibault; Muriel Philipps; Serge Vicaire; Bernard Jost; Bjarne Udd; John W Day; Denis Duboc; Karim Wahbi; Tsuyoshi Matsumura; Harutoshi Fujimura; Hideki Mochizuki; François Deryckere; Takashi Kimura; Nobuyuki Nukina; Shoichi Ishiura; Vincent Lacroix; Amandine Campan-Fournier; Vincent Navratil; Emilie Chautard; Didier Auboeuf; Minoru Horie; Keiji Imoto; Kuang-Yung Lee; Maurice S Swanson; Adolfo Lopez de Munain; Shin Inada; Hideki Itoh; Kazuo Nakazawa; Takashi Ashihara; Eric Wang; Thomas Zimmer; Denis Furling; Masanori P Takahashi; Nicolas Charlet-Berguerand
Journal:  Nat Commun       Date:  2016-04-11       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.